BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 15717997)

  • 1. Management of bone metastases in breast cancer.
    Lipton A
    Curr Treat Options Oncol; 2005 Mar; 6(2):161-71. PubMed ID: 15717997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bisphosphonates in breast cancer.
    Coleman RE
    Ann Oncol; 2005 May; 16(5):687-95. PubMed ID: 15802276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonates for breast cancer.
    Pavlakis N; Schmidt R; Stockler M
    Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of zoledronic acid and pamidronate in breast cancer patients: a comparative analysis of randomized phase III trials.
    Coleman RE
    Am J Clin Oncol; 2002 Dec; 25(6 Suppl 1):S25-31. PubMed ID: 12562048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of intravenous bisphosphonates for patients with breast cancer metastatic to bone: a review of randomized, double-blind, phase III trials.
    Gordon DH
    Clin Breast Cancer; 2005 Jun; 6(2):125-31. PubMed ID: 16001990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimising treatment of bone metastases by Aredia(TM) and Zometa(TM).
    Coleman RE
    Breast Cancer; 2000; 7(4):361-9. PubMed ID: 11114866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.
    Ibrahim A; Scher N; Williams G; Sridhara R; Li N; Chen G; Leighton J; Booth B; Gobburu JV; Rahman A; Hsieh Y; Wood R; Vause D; Pazdur R
    Clin Cancer Res; 2003 Jul; 9(7):2394-9. PubMed ID: 12855610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonate therapy in the oncology setting.
    Lipton A
    Expert Opin Emerg Drugs; 2003 Nov; 8(2):469-88. PubMed ID: 14662000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
    Rosen LS; Gordon D; Kaminski M; Howell A; Belch A; Mackey J; Apffelstaedt J; Hussein MA; Coleman RE; Reitsma DJ; Chen BL; Seaman JJ
    Cancer; 2003 Oct; 98(8):1735-44. PubMed ID: 14534891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proven efficacy of zoledronic acid in the treatment of bone metastases in patients with breast cancer and other malignancies.
    Cameron D
    Breast; 2003 Aug; 12 Suppl 2():S22-9. PubMed ID: 14659140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.
    Rosen LS; Gordon D; Kaminski M; Howell A; Belch A; Mackey J; Apffelstaedt J; Hussein M; Coleman RE; Reitsma DJ; Seaman JJ; Chen BL; Ambros Y
    Cancer J; 2001; 7(5):377-87. PubMed ID: 11693896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing bisphosphonate therapy in patients with breast cancer on endocrine therapy.
    Harvey HA
    Semin Oncol; 2004 Dec; 31(6 Suppl 12):23-30. PubMed ID: 15719598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial.
    Kohno N; Aogi K; Minami H; Nakamura S; Asaga T; Iino Y; Watanabe T; Goessl C; Ohashi Y; Takashima S
    J Clin Oncol; 2005 May; 23(15):3314-21. PubMed ID: 15738536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisphosphonates for breast cancer.
    Pavlakis N; Stockler M
    Cochrane Database Syst Rev; 2002; (1):CD003474. PubMed ID: 11869664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints.
    Major PP; Cook R
    Am J Clin Oncol; 2002 Dec; 25(6 Suppl 1):S10-8. PubMed ID: 12562046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of bisphosphonates in breast and prostate cancers.
    Brown JE; Neville-Webbe H; Coleman RE
    Endocr Relat Cancer; 2004 Jun; 11(2):207-24. PubMed ID: 15163299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zoledronic acid for the treatment of bone metastases in patients with breast cancer and other solid tumors.
    Lacerna L; Hohneker J
    Semin Oncol; 2003 Oct; 30(5 Suppl 16):150-60. PubMed ID: 14613036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in supportive care of patients with cancer and bone metastases: nursing implications of zoledronic acid.
    Maxwell C; Swift R; Goode M; Doane L; Rogers M
    Clin J Oncol Nurs; 2003; 7(4):403-8. PubMed ID: 12929273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind, phase II, exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high-risk bone metastases from breast cancer.
    Jacobs C; Kuchuk I; Bouganim N; Smith S; Mazzarello S; Vandermeer L; Dranitsaris G; Dent S; Gertler S; Verma S; Song X; Simos S; Cella D; Clemons M
    Breast Cancer Res Treat; 2016 Jan; 155(1):77-84. PubMed ID: 26643085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale for the use of bisphosphonates in osteoblastic and osteolytic bone lesions.
    Body JJ
    Breast; 2003 Aug; 12 Suppl 2():S37-44. PubMed ID: 14659142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.